Accenture (NYSE:ACN) has invested, through Accenture Ventures, in Iridius, an enterprise AI infrastructure company that designs compliant-by-design AI solutions for highly regulated industries, including life sciences and pharmaceuticals sectors. As part of this investment, Accenture and Iridius will also form a strategic partnership to support life sciences organizations in scaling AI adoption while ensuring compliance, traceability, and auditability are integrated at every stage.